25,000 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Bought by Knott David M Jr

Knott David M Jr bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the company’s stock, valued at approximately $479,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Viridian Therapeutics in the third quarter worth $208,000. Intech Investment Management LLC bought a new position in shares of Viridian Therapeutics during the 3rd quarter worth about $422,000. Charles Schwab Investment Management Inc. raised its position in shares of Viridian Therapeutics by 6.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 516,213 shares of the company’s stock valued at $11,744,000 after buying an additional 32,292 shares during the last quarter. FMR LLC lifted its stake in shares of Viridian Therapeutics by 16.8% in the third quarter. FMR LLC now owns 11,183,478 shares of the company’s stock valued at $254,424,000 after buying an additional 1,610,130 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Viridian Therapeutics by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock worth $318,000 after buying an additional 2,036 shares in the last quarter.

Viridian Therapeutics Price Performance

Shares of VRDN stock opened at $13.48 on Tuesday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.13 and a beta of 1.05. The firm’s 50 day moving average is $16.66 and its 200-day moving average is $19.66. Viridian Therapeutics, Inc. has a 1 year low of $11.40 and a 1 year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on VRDN shares. Royal Bank of Canada upped their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.